Pharmosa Biopharm Inc (6875) Fair Value & Analysis
Healthcare · TW · Market cap 4.6B TWD
Fair value as of: Jul 22, 2026
From 1 valuation models · updated 19 days ago
Share price −11.4% over the past month.
Below-average quality, and screening another 76% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (9.81 TWD). The favourable scenario is already priced in.
- Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (5.18 TWD to 9.81 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
54‑month range 30.55 TWD – 134.97 TWD · fair‑value band 5.18 TWD – 9.81 TWD · the 33.00 TWD price screens above the 7.85 TWD fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Pharmosa Biopharm Inc (6875) currently trades at 33.00 TWD, while our model-based Fair Value estimate is 7.85 TWD, implying the stock looks roughly 76.2% overvalued today. The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 69.1M TWD. Revenue declined 59.3% year over year. It earns a return on equity of -23.3%. The balance sheet holds a net cash position of 830M TWD. Fundamentals as of Jul 22, 2026
Our scenario range runs from 5.18 TWD (bear case) to 9.81 TWD (bull case); at 33.00 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 49% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -76%, 6875 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 6875 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 32 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease.
Full company description
Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was founded in 2000 and is headquartered in Taipei, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pharmosa Biopharm Inc reported revenue of 67.3M TWD in FY2025 versus 0 TWD in FY2022. Reported net income was −384M TWD in FY2025.
6875 screens 76% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Pharmosa Biopharm Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pharmosa Biopharm Inc (6875) overvalued or undervalued?
What is the fair value of 6875?
What is the quality score of 6875?
What is the revenue of Pharmosa Biopharm Inc (6875)?
What is the net profit margin of 6875?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Pharmosa Biopharm Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.